Theralase Technologies Inc.

Summary:

• Theralase® is focused on providing the next standard of care treatment for bladder cancer. The 10th most common cancer in the world (6th in men).

• Theralase® combines a patented light-sensitive drug and proprietary laser system that has the ability to destroy cancer directly in the bladder.

• Theralase® has enrolled and provided the primary study treatment for 59 / 100 patients in a FDA Phase II registration clinical study, that if successful will grant Theralase commercial access to cancer markets worth between an estimated $1 to $7 B annually.